Physician profile
William E Holcomb
NPI 1427037605
$10,648.91
in general payments reported to CMS, 2019-2025
26 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $330 · 2021: $1,228 · 2022: $2,618 · 2023: $2,393 · 2024: $1,233 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,258.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,113.80 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Johnson & Johnson Surgical Vision, INC. | $1,229.75 | 2019-2025 | Tecnis Simplicity, Amo Phaco Needle, Catalys System |
| New World Medical,INC. | $1,129.36 | 2022-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Abbvie INC. | $1,020.44 | 2022-2025 | |
| Allergan, INC. | $455.95 | 2019-2022 | |
| Biotissue Holdings INC. | $406.87 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $196.34 | 2019-2023 | Cequa |
| Rxsight INC | $179.02 | 2024 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Glaukos Corporation | $138.52 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $103.69 | 2022-2025 | Xiidra, Miebo, Alrex |
| Tarsus Pharmaceuticals, INC. | $94.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.33 | 2019-2020 | |
| Oyster Point Pharma, INC. | $76.36 | 2022-2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Omeros Corporation | $56.62 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $48.84 | 2021 | |
| Aerie Pharmaceuticals, INC. | $47.89 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $33.79 | 2023 | Clarus, Humphrey Hfa |
| Novartis Pharmaceuticals Corporation | $33.69 | 2020-2022 | |
| Horizon Therapeutics Plc | $27.05 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $25.37 | 2022 | |
| Akorn Operating Company LLC | $21.95 | 2021 | |
| Dompe US, INC. | $20.91 | 2024 | Oxervate |
| Astellas Pharma US INC | $16.92 | 2025 | Izervay |
| Iridex Corporation | $16.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Holcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.